From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
Open Access
Abstract
Acute myeloid leukemia (AML) is a heterogeneous group of clonal disorders characterized by abnormal proliferation of undifferentiated myeloid progenitors, impaired hematopoiesis, and variable response to therapy. To date, only about 30% of adult patients with AML become long-term survivors and relapse and/or disease refractoriness are the major cause of treatment failure. Thus, this is an urgent unmet clinical need and new drugs are envisaged in order to ameliorate disease survival outcomes. Here, we review the latest therapeutic approaches (investigational and approved agents) for AML treatment. A specific focus will be given to molecularly targeted therapies for AML as a representation of possible agents for precision medicine. We will discuss experimental and preclinical data for FLT3, IDH1, BCL-2, Hedgehog pathway inhibitors, and epitherapy.Keywords
Funding Information
- AA&MDSIF (.)
- Lilli Foundation (.)
- VeloSano Pilot Award (.)
- Vera and Joseph Dresner Foundation–MDS (.)
This publication has 106 references indexed in Scilit:
- Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapiesBlood Cancer Journal, 2012
- Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II studyLeukemia & Lymphoma, 2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factorsBlood, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profileGenes, Chromosomes and Cancer, 2005
- The IARC TP53 database: New online mutation analysis and recommendations to usersHuman Mutation, 2002